



Press Release
September 2007

PARACETAMOL AGREEMENT BETWEEN ETHYPHARM AND ACTAVIS

The first orodispersible tablet to be launched in the Ukraine

Ethypharm has recently signed a licensing agreement with the Icelandic Laboratory Actavis for the marketing of Paracetamol Flashtab® 125 mg, 250 mg & 500 mg.

Initially concluded in 2003, the Agreement with the BalkanPharma Laboratory was an undeniable point of departure for both laboratories in the marketing of the product for this new territory.

Recently launched, this product is the first orodispersible paracetamol tablet to be sold in the Ukraine Under the brand name « Rapidol », the disintegrating paracetamol is destined for children. It has pain-relief agents with a very light anti-inflammatory action targetted on the central nervous system. It therefore permits a more gentle action compared to other similar medicinal products such as Analgin or Aspirin (acetysal). This medicinal product is indicated for the treatment of pain (headache, tooth ache and muscular pain) or fever.

Developed on the basis of the Flashtab® formulation, Rapidol is a flavoured tablet which melts rapidly in the mouth without water, and which has several advantages in terms of acceptability and precision of dosage and safety. In using the Ethypharm Flashtab® technology which facilitates administration and masks the bitterness of the active substance, both companies had a mutual objective of responding to a targeted need in terms of medicinal products for children.

«We are happy to have signed this Agreement with Actavis» declared Bruno Delie, Ethypharm's Business & Marketing Director. « Actavis launched Paracetamol in Bulgaria with success. Its position as leader should enable us to acquire a position in the developing market which is still little exploited in the Ukraine » he added.

Pediatric medicines are not readily available in the Ukraine. With the Ethypharm Flashtab® formulation, the Actavis Laboratory should therefore able to acquire this little represented segment: which makes Rapidol a particularly interesting product since it will enable our Partner to reinforce and diversify its range of products.

Press Contact:

Caroline Guinet,
Corporate Communication
guinet.caroline@ethypharm.com
+ 33 1 41 12 32 82